MAIA Biotechnology (MAIA) Total Liabilities (2021 - 2026)

MAIA Biotechnology (MAIA) has reported Total Liabilities for 6 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities rose 9.21% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $7.6 million (up 9.21% YoY), while the FY2025 annual figure was $7.3 million, up 12.39% from the prior year.
• Total Liabilities grew to $7.6 million in Q1 2026 per MAIA's latest filing, from $7.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $14.5 million in Q1 2024 and bottomed at $2.7 million in Q3 2022.
• Historically, Total Liabilities has averaged $6.6 million across 5 years, with a median of $7.0 million in 2023.
• Annual changes were most pronounced in 2024 — Total Liabilities surged 262.85% — and 2025, when it plunged 52.2%.
• MAIA Biotechnology's Total Liabilities stood at $3.5 million in 2022, then surged by 101.73% to $7.1 million in 2023, then declined by 8.02% to $6.5 million in 2024, then climbed by 12.39% to $7.3 million in 2025, then climbed by 3.15% to $7.6 million in 2026.
• Business Quant data shows MAIA's Total Liabilities at $7.6 million in Q1 2026, $7.3 million in Q4 2025, and $11.7 million in Q3 2025.